electroCore Submits Premarket Notification Seeking Clearance From FDA For Its Quell Wearable Neuromodulation Platform To Treat Chronic Chemotherapy-Induced Peripheral Neuropathy

electroCore, Inc. (NASDAQ:ECOR), ("electroCore" or the "Company"), a bioelectronic technology company, today announced that it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) seeking 510(k) clearance for its Quell® wearable neuromodulation platform ("Quell") for the treatment of chronic chemotherapy-induced peripheral neuropathy (CIPN).